<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bedimo RJ</submitter><funding>NCATS NIH HHS</funding><funding>NIAAA NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>325-334</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7775280</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>35(2)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>To determine whether statin exposure is associated with decreased cancer and mortality risk among persons with HIV (PWH) and uninfected persons. Statins appear to have immunomodulatory and anti-inflammatory effects and may reduce cancer risk, particularly among PWH as they experience chronic inflammation and immune activation.&lt;h4>Design&lt;/h4>Propensity score-matched cohort of statin-exposed and unexposed patients from 2002 to 2017 in the Veterans Aging Cohort Study (VACS), a large cohort with cancer registry linkage and detailed pharmacy data.&lt;h4>Methods&lt;/h4>We calculated Cox regression hazard ratios (HRs) and 95% confidence intervals (CI) associated with statin use for all cancers, microbial cancers (associated with bacterial or oncovirus coinfection), nonmicrobial cancer</pubmed_abstract><journal>AIDS (London, England)</journal><pubmed_title>Statin exposure and risk of cancer in people with and without HIV infection.</pubmed_title><pmcid>PMC7775280</pmcid><funding_grant_id>U01 AA020790</funding_grant_id><funding_grant_id>U01 AA013566</funding_grant_id><funding_grant_id>U01 AA026224</funding_grant_id><funding_grant_id>UL1 TR001863</funding_grant_id><funding_grant_id>R01 CA210806</funding_grant_id><funding_grant_id>U24 AA020794</funding_grant_id><funding_grant_id>R01 CA206465</funding_grant_id><pubmed_authors>Rodriguez-Barradas MC</pubmed_authors><pubmed_authors>Bedimo RJ</pubmed_authors><pubmed_authors>Rentsch CT</pubmed_authors><pubmed_authors>Goetz MB</pubmed_authors><pubmed_authors>Justice AC</pubmed_authors><pubmed_authors>Tate JP</pubmed_authors><pubmed_authors>Gibert C</pubmed_authors><pubmed_authors>Park LS</pubmed_authors><pubmed_authors>Sigel K</pubmed_authors><pubmed_authors>Shebl FM</pubmed_authors><pubmed_authors>Brown ST</pubmed_authors><pubmed_authors>Butt AA</pubmed_authors><pubmed_authors>Crothers K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Statin exposure and risk of cancer in people with and without HIV infection.</name><description>&lt;h4>Objective&lt;/h4>To determine whether statin exposure is associated with decreased cancer and mortality risk among persons with HIV (PWH) and uninfected persons. Statins appear to have immunomodulatory and anti-inflammatory effects and may reduce cancer risk, particularly among PWH as they experience chronic inflammation and immune activation.&lt;h4>Design&lt;/h4>Propensity score-matched cohort of statin-exposed and unexposed patients from 2002 to 2017 in the Veterans Aging Cohort Study (VACS), a large cohort with cancer registry linkage and detailed pharmacy data.&lt;h4>Methods&lt;/h4>We calculated Cox regression hazard ratios (HRs) and 95% confidence intervals (CI) associated with statin use for all cancers, microbial cancers (associated with bacterial or oncovirus coinfection), nonmicrobial cancer</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2025-04-18T15:10:36.35Z</modification><creation>2022-02-11T15:50:23.933Z</creation></dates><accession>S-EPMC7775280</accession><cross_references><pubmed>33181533</pubmed><doi>10.1097/qad.0000000000002748</doi><doi>10.1097/QAD.0000000000002748</doi></cross_references></HashMap>